# DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

> **NCT04567420** · PHASE2 · RECRUITING · sponsor: **Criterium, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Adjuvant Therapy

## Key facts

- **NCT ID:** NCT04567420
- **Lead sponsor:** Criterium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-09
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04567420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04567420, "DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04567420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*